Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Observational Study on Lutetium (177Lu) Vipivotide Tetraxetan to Treat Metastatic Castration Resistant Prostate Cancer |
Metastatic Castration Resistant Prostate Cancer | Italy | NCT07093801 | |
Evaluation of 1-Year Clinical Outcomes With Early Inclisiran Initiation in Post-MI Patients |
Myocardial Infarction | Russia | NCT07142265 | |
Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients |
Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase3 | Brazil Colombia Germany Italy Netherlands United States View all |
NCT06934967 |
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN |
Primary Immunoglobulin A Nephropathy (IgAN) | Phase3 | Australia China Hong Kong Israel Japan United States View all |
NCT06994845 |
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes |
Acute Coronary Syndrome | Phase3 | Australia Canada China France Germany Hong Kong Hungary India Japan Poland South Korea Spain Switzerland View all |
NCT07102628 |
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors |
Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer, Soft Tissue Sarcoma | Phase1 | Canada France Israel Singapore View all |
NCT07261631 |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease |
Chronic Kidney Disease | Phase1 | Germany United States |
NCT07235059 |
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) |
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase1, Phase2 | Australia China France Germany Hong Kong Hungary Italy South Korea Spain Turkey (Türkiye) United States View all |
NCT07190300 |
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC |
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy | Phase1, Phase2 | Australia Japan Spain United States View all |
NCT07226986 |
A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation |
Atrial Fibrillation | Phase2 | Canada China Germany Netherlands Singapore United Kingdom United States View all |
NCT07217067 |